Cargando…
2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients
BACKGROUND: Herpes zoster (HZ) and its complications can have a substantial impact on patients’ quality of life (QoL), particularly in immunocompromised patients. The vaccine efficacy (VE) of an adjuvanted recombinant zoster vaccine (RZV) was studied in a randomized, placebo-controlled, phase 3 stud...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253678/ http://dx.doi.org/10.1093/ofid/ofy210.2135 |
_version_ | 1783373552071737344 |
---|---|
author | Curran, Desmond Anagnostopoulos, Achilles Barista, Ibrahim Bastidas, Adriana Chandrasekar, Pranatharthi Dickinson, Michael Heras, Inmaculada Idrissi, Mohamed El Matthews, Sean Milliken, Samuel Coll, Jorge Monserrat Matilla, Maria Belen Navarro Oostvogels, Lidia Quiel, Dimas Rowley, Scott Sabry, Waleed Selleslag, Dominik Szer, Jeff Theunissen, Koen Yegin, Zeynep Arzu Yeh, Su-Peng Young, Jo-Anne Zaja, Francesco |
author_facet | Curran, Desmond Anagnostopoulos, Achilles Barista, Ibrahim Bastidas, Adriana Chandrasekar, Pranatharthi Dickinson, Michael Heras, Inmaculada Idrissi, Mohamed El Matthews, Sean Milliken, Samuel Coll, Jorge Monserrat Matilla, Maria Belen Navarro Oostvogels, Lidia Quiel, Dimas Rowley, Scott Sabry, Waleed Selleslag, Dominik Szer, Jeff Theunissen, Koen Yegin, Zeynep Arzu Yeh, Su-Peng Young, Jo-Anne Zaja, Francesco |
author_sort | Curran, Desmond |
collection | PubMed |
description | BACKGROUND: Herpes zoster (HZ) and its complications can have a substantial impact on patients’ quality of life (QoL), particularly in immunocompromised patients. The vaccine efficacy (VE) of an adjuvanted recombinant zoster vaccine (RZV) was studied in a randomized, placebo-controlled, phase 3 study in adult hematopoietic stem cell transplant (HSCT) recipients (NCT01610414). The VE in preventing HZ cases was 68.2% (95% CI: 55.6%–77.5%). Herein we report the impact of the vaccine on patients’ quality of life (QoL) associated with HZ episodes. METHODS: HSCT recipients were randomized 1:1 to receive 2 doses of RZV or placebo, given 1–2 months apart and followed for the occurrence of HZ. QoL parameters were measured by the Short-Form health survey (SF-36) and Euro-Quality of Life-5 Dimension (EQ-5D) at baseline, 1 month and 1 year post-dose 2, as well as during suspected HZ episodes in conjunction with the Zoster Brief Pain Inventory (ZBPI). For confirmed HZ cases, QoL scores were compared between the vaccine and placebo groups. The RZV impact in reducing the ZBPI Burden of Illness and Burden of Interference scores was estimated in patients in the modified total vaccinated cohort (mTVC). The 2 scores were calculated from the area under the curve (Days 0 to 182) of the ZBPI Worst Pain and ZBPI Activities of Daily Living scores, respectively, assuming a score of 0 for patients who did not have a confirmed HZ episode. RESULTS: Both the ZBPI maximum Worst Pain and Average Pain scores were significantly lower in the vaccine than placebo group (Table 1), suggesting less burden in breakthrough HZ cases following RZV. Consequently, the HZ Burden of Illness and Burden of Interference VE estimates were higher than the HZ VE estimate. RZV showed statistically significantly better QoL scores than placebo one week following rash-onset among patients with confirmed HZ, i.e., SF-36 bodily pain, social functioning, role emotional, mental health and mental component scores, and the EQ-5D Utility Score. [Image: see text] CONCLUSION: In addition to reducing the risk of HZ and HZ complications, RZV significantly reduces the impact of HZ on patient’s QoL in those who develop breakthrough disease. Funding: GlaxoSmithKline Biologicals SA. DISCLOSURES: D. Curran, GlaxoSmithKline: Employee, GSK Shares and Salary. A. Bastidas, GSK: Employee, Salary. M. El Idrissi, GSK: Employee and Shareholder, Salary. S. Matthews, GSK group of companies: Consultant, Consulting fee. L. Oostvogels, GSK group of companies: Employee, Salary and stock and stock option. J. A. Young, GSK: Investigator, The University of Minnesota is reimbursed for contract costs associated with conducting clinical trials of vaccine. I receive no personal financial benefit. |
format | Online Article Text |
id | pubmed-6253678 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62536782018-11-28 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients Curran, Desmond Anagnostopoulos, Achilles Barista, Ibrahim Bastidas, Adriana Chandrasekar, Pranatharthi Dickinson, Michael Heras, Inmaculada Idrissi, Mohamed El Matthews, Sean Milliken, Samuel Coll, Jorge Monserrat Matilla, Maria Belen Navarro Oostvogels, Lidia Quiel, Dimas Rowley, Scott Sabry, Waleed Selleslag, Dominik Szer, Jeff Theunissen, Koen Yegin, Zeynep Arzu Yeh, Su-Peng Young, Jo-Anne Zaja, Francesco Open Forum Infect Dis Abstracts BACKGROUND: Herpes zoster (HZ) and its complications can have a substantial impact on patients’ quality of life (QoL), particularly in immunocompromised patients. The vaccine efficacy (VE) of an adjuvanted recombinant zoster vaccine (RZV) was studied in a randomized, placebo-controlled, phase 3 study in adult hematopoietic stem cell transplant (HSCT) recipients (NCT01610414). The VE in preventing HZ cases was 68.2% (95% CI: 55.6%–77.5%). Herein we report the impact of the vaccine on patients’ quality of life (QoL) associated with HZ episodes. METHODS: HSCT recipients were randomized 1:1 to receive 2 doses of RZV or placebo, given 1–2 months apart and followed for the occurrence of HZ. QoL parameters were measured by the Short-Form health survey (SF-36) and Euro-Quality of Life-5 Dimension (EQ-5D) at baseline, 1 month and 1 year post-dose 2, as well as during suspected HZ episodes in conjunction with the Zoster Brief Pain Inventory (ZBPI). For confirmed HZ cases, QoL scores were compared between the vaccine and placebo groups. The RZV impact in reducing the ZBPI Burden of Illness and Burden of Interference scores was estimated in patients in the modified total vaccinated cohort (mTVC). The 2 scores were calculated from the area under the curve (Days 0 to 182) of the ZBPI Worst Pain and ZBPI Activities of Daily Living scores, respectively, assuming a score of 0 for patients who did not have a confirmed HZ episode. RESULTS: Both the ZBPI maximum Worst Pain and Average Pain scores were significantly lower in the vaccine than placebo group (Table 1), suggesting less burden in breakthrough HZ cases following RZV. Consequently, the HZ Burden of Illness and Burden of Interference VE estimates were higher than the HZ VE estimate. RZV showed statistically significantly better QoL scores than placebo one week following rash-onset among patients with confirmed HZ, i.e., SF-36 bodily pain, social functioning, role emotional, mental health and mental component scores, and the EQ-5D Utility Score. [Image: see text] CONCLUSION: In addition to reducing the risk of HZ and HZ complications, RZV significantly reduces the impact of HZ on patient’s QoL in those who develop breakthrough disease. Funding: GlaxoSmithKline Biologicals SA. DISCLOSURES: D. Curran, GlaxoSmithKline: Employee, GSK Shares and Salary. A. Bastidas, GSK: Employee, Salary. M. El Idrissi, GSK: Employee and Shareholder, Salary. S. Matthews, GSK group of companies: Consultant, Consulting fee. L. Oostvogels, GSK group of companies: Employee, Salary and stock and stock option. J. A. Young, GSK: Investigator, The University of Minnesota is reimbursed for contract costs associated with conducting clinical trials of vaccine. I receive no personal financial benefit. Oxford University Press 2018-11-26 /pmc/articles/PMC6253678/ http://dx.doi.org/10.1093/ofid/ofy210.2135 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Curran, Desmond Anagnostopoulos, Achilles Barista, Ibrahim Bastidas, Adriana Chandrasekar, Pranatharthi Dickinson, Michael Heras, Inmaculada Idrissi, Mohamed El Matthews, Sean Milliken, Samuel Coll, Jorge Monserrat Matilla, Maria Belen Navarro Oostvogels, Lidia Quiel, Dimas Rowley, Scott Sabry, Waleed Selleslag, Dominik Szer, Jeff Theunissen, Koen Yegin, Zeynep Arzu Yeh, Su-Peng Young, Jo-Anne Zaja, Francesco 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title | 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title_full | 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title_fullStr | 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title_full_unstemmed | 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title_short | 2482. Impact of a Recombinant Zoster Vaccine on Quality of Life: Data from a Randomized, Placebo-Controlled, Phase 3 Trial in Adult Hematopoietic Stem Cell Transplant Recipients |
title_sort | 2482. impact of a recombinant zoster vaccine on quality of life: data from a randomized, placebo-controlled, phase 3 trial in adult hematopoietic stem cell transplant recipients |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253678/ http://dx.doi.org/10.1093/ofid/ofy210.2135 |
work_keys_str_mv | AT currandesmond 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT anagnostopoulosachilles 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT baristaibrahim 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT bastidasadriana 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT chandrasekarpranatharthi 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT dickinsonmichael 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT herasinmaculada 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT idrissimohamedel 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT matthewssean 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT millikensamuel 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT colljorgemonserrat 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT matillamariabelennavarro 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT oostvogelslidia 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT quieldimas 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT rowleyscott 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT sabrywaleed 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT selleslagdominik 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT szerjeff 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT theunissenkoen 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT yeginzeyneparzu 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT yehsupeng 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT youngjoanne 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT zajafrancesco 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients AT 2482impactofarecombinantzostervaccineonqualityoflifedatafromarandomizedplacebocontrolledphase3trialinadulthematopoieticstemcelltransplantrecipients |